Want to see HK:9989 full AI Analyst Report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) AI Stock Analysis
Top Page
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
(HKEX:9989)
The score is primarily supported by improved profitability versus 2023, stronger recent cash generation, and moderate leverage. Offsetting this are contracting TTM revenue and margin compression that depress ROE, alongside weak technical trend signals and a very high P/E that makes the stock sensitive to any earnings disappointment (despite a supportive dividend yield).
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 13.29B
- Dividend Yield
- 4.22%
- Average Volume (3M)
- 592.32K
- Price to Earnings (P/E)
- 185.1
- Beta (1Y)
- 0.73
- Revenue Growth
- 3.10%
- EPS Growth
- -46.64%
- Country
- Hong Kong
- Employees
- 2,150
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wid...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Statement Overview
Summary
Financials are mixed: profitability has recovered from the 2023 downturn and cash generation is a relative strength (TTM FCF up ~17.5% with ~0.95x FCF-to-net-income). However, TTM revenue is down (~-3.0%) and margins have compressed meaningfully versus 2024–2025, keeping ROE low (~1.6%). Leverage is moderate and improved versus earlier years.
Income Statement
56NeutralBalance Sheet
63PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.08B | 5.48B | 5.28B | 5.45B | 7.16B | 6.37B |
| Gross Profit | 1.73B | 1.74B | 1.76B | 1.80B | 2.33B | 2.03B |
| EBITDA | 455.12M | 846.59M | 1.20B | ― | 1.37B | 726.64M |
| Net Income | 189.81M | 349.49M | 646.74M | ― | 727.43M | 240.79M |
Balance Sheet | ||||||
| Total Assets | 16.62B | 16.63B | 17.34B | 19.20B | 20.81B | 19.11B |
| Cash, Cash Equivalents and Short-Term Investments | 4.27B | 2.83B | 2.56B | 2.27B | 3.45B | 3.93B |
| Total Debt | 2.86B | 2.11B | 2.98B | 3.78B | 6.46B | 5.65B |
| Total Liabilities | 4.52B | 4.55B | 5.14B | 7.22B | 8.41B | 7.58B |
| Stockholders Equity | 12.04B | 12.03B | 12.15B | 11.91B | 12.31B | 11.41B |
Cash Flow | ||||||
| Free Cash Flow | 1.67B | 1.59B | 1.99B | -46.66M | -979.03M | -200.49M |
| Operating Cash Flow | 1.77B | 1.71B | 2.19B | 398.22M | -756.61M | -6.63M |
| Investing Cash Flow | -1.26B | -872.75M | -415.05M | 1.22B | 249.84M | 719.93M |
| Financing Cash Flow | -461.24M | -1.09B | -2.14B | -1.21B | 329.56M | -501.08M |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9989, the sentiment is Neutral. The current price of 3.94 is above the 20-day moving average (MA) of 3.89, below the 50-day MA of 4.05, and below the 200-day MA of 4.48, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 65.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9989.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Peers Comparison
Overall Rating
HK:151377Outperform
HK:332068Neutral
HK:086761Neutral
HK:219657Neutral
HK:046056Neutral- HK:998956Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1513 | 77Outperform | HKD 26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% |
| HK:3320 | 68Neutral | HKD 29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% |
| HK:0867 | 61Neutral | HKD 23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% |
| HK:2196 | 57Neutral | HKD 65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% |
| HK:0460 | 56Neutral | HKD 6.76B | 18.42 | 5.03% | 1.50% | 29.68% | ― |
| HK:9989 | 56Neutral | HKD 14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9989 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H | 3.94 | -1.40 | -26.20% | |
| HK:0867 | China Medical System Holdings | 9.81 | -3.65 | -27.10% | |
| HK:1513 | Livzon Pharmaceutical Group Class H | 23.18 | -5.02 | -17.81% | |
| HK:2196 | Shanghai Fosun Pharmaceutical (Group) Co Class H | 16.47 | -6.58 | -28.55% | |
| HK:0460 | Sihuan Pharmaceutical Holdings Group | 0.72 | -0.75 | -50.71% | |
| HK:3320 | China Resources Pharmaceutical Group Ltd. | 4.63 | -0.11 | -2.26% |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Corporate Events
Shenzhen Hepalink Files Unaudited Third-Quarter 2026 Report in Hong Kong
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for the nine months ended September 30, 2026, prepared under PRC Accounting Standards. The disclosure is made in compliance with Hong Kong securities r...
Shenzhen Hepalink reshuffles Hong Kong company secretary and process agent roles
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced changes to its corporate governance roles, with joint company secretary and authorised representative Ms. Chan Sze Ting resigning due to work arrangements and, along with Ms. Wong Wai Yee...
Hepalink Sets Board Meeting to Approve Third-Quarter Results
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for October 29, 2026 to review and approve the group’s third quarterly results for the nine months ended September 30, 2026. The approval and subsequent publication...
Hepalink Shareholders Back Higher Wealth Management and Bank Credit Limits at 2026 EGM
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. reported that shareholders approved all resolutions at its first extraordinary general meeting of 2026 held in Shenzhen on September 22. The meeting, which complied with PRC company law and Hong Kong l...
Hepalink convenes 2026 EGM to expand wealth management and credit lines
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has called its first extraordinary general meeting of 2026 for September 22 in Shenzhen, inviting shareholders of its H shares to vote on key financial management resolutions. The meeting will consider...
Hepalink Profit Slumps on Lower Revenue Despite Margin Improvement
Shenzhen Hepalink Pharmaceutical Group reported interim unaudited revenue of RMB2.56 billion for the six months ended June 30, 2026, an 8.2% decline from a year earlier, while profit attributable to shareholders fell 36.6% to RMB275.3 million. Despit...
Hepalink Raises Wealth Management Fund Limit, Trims Guarantee Cap
Shenzhen Hepalink Pharmaceutical Group plans to raise the cap on its use of internal funds for purchasing wealth management products and managing cash flow from RMB2.5 billion to RMB3.5 billion, effective until its 2026 annual general meeting, to enh...
Shenzhen Hepalink Sets Board Meeting to Review Interim Results and Dividend
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for August 28, 2026 to review and approve the Group’s interim results for the six months ended June 30, 2026, and to decide on the publication of those results.The b...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026